Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALX Oncology Holdings (ALXO) Stock Price & Analysis
276 Followers
ALXO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.94 - $17.47
Previous Close$15.36
Volume1.28M
Average Volume (3M)507.38K
Market Cap
$775.66M
Enterprise Value$602.56M
Total Cash (Recent Filing)$182.74M
Total Debt (Recent Filing)$9.64M
Price to Earnings (P/E)-4.1
Beta1.76
Next Earnings
May 08, 2024EPS Estimate
-$0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.74
Shares Outstanding50,152,082
10 Day Avg. Volume531,329
30 Day Avg. Volume507,379
Standard Deviation0.30
R-Squared0.05
Alpha0.00924
Financial Highlights & Ratios
Price to Book (P/B)4.39
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.69
Forecast
1Y Price Target
$19.80Price Target Upside28.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
ALX Oncology Holdings News
PremiumCompany Announcements
ALX Oncology Board Reshuffles Following Director Resignations
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalysts maintain a Buy rating of ALXO with a 12-month price target of $20, based on a risk-adjusted net present value analysis of projected future revenues from evorpacept.
Clinical Trial ResultsEvorpacept combined with SOC shows potential in difficult r/r NHL population, with a CR rate of 83%, which compared favorably to the benchmark rate of 34%.
Drug Safety And EfficacyThe combination of evorpacept and standard-of-care showed promising response rates and a manageable safety profile in the study.
Bears Say
Clinical Trial OutcomesThe FDA placed a clinical hold on all programs evaluating Gilead’s magrolimab... the treatment combination showed futility and led to an increased risk of death driven by infections and respiratory failure.
Drug Efficacy And SafetyThe study faced some treatment-emergent adverse events and cycle delays, although these were predominantly of low grades and manageable.
Financial PerformanceALX Oncology reported a net loss of $0.93 per share for 4Q23, which was slightly higher than the consensus estimated net loss.
---
Ownership Overview
30.80% Insiders
21.91% Mutual Funds
14.63% Other Institutional Investors
32.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $3.94 and its highest was $17.47 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
Currently, no data Available
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is May 08, 2024 which is today.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Mar 07, 2024. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.877 by -$0.053.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -$0.82.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 50,498,817 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.877. Following the earnings report the stock price went down -6.342%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
---
ALX Oncology Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.80 (28.91% Upside)
$19.80 (28.91% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 78%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $49.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.98%
12-Months-Change
Fundamentals
Return on Equity
-70.97%
Trailing 12-Months
Asset Growth
-20.86%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
---
ALXO Stock 12 Months Forecast
Average Price Target
$19.80
▲(28.91% Upside)
Technical Analysis
Best Analysts Covering ALXO
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+25.17%
assigned a buy rating 28 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +25.17% per trade.
---